Notes on AI rollouts in healthcare and project delivery.https://miguelrujas.com/en-GBhttps://miguelrujas.com/en/notes/should-we-switch-models/https://miguelrujas.com/en/notes/should-we-switch-models/Changing the model behind a production agent costs far more than one line of code. Before migrating, I look at three things: cost, real improvement, and whether anything is forcing us.Wed, 30 Sep 2026 00:00:00 GMThttps://miguelrujas.com/en/notes/one-percent-of-trials-use-ai/https://miguelrujas.com/en/notes/one-percent-of-trials-use-ai/The number people will share is 1%. The part worth reading is who signs those studies: hospitals and universities, not industry.Sun, 23 Aug 2026 00:00:00 GMThttps://miguelrujas.com/en/notes/emulatrx-agents-clinical-trials/https://miguelrujas.com/en/notes/emulatrx-agents-clinical-trials/A multi-agent system that designs trials from real-world data. How this architecture will reach clinical research: task by task, not as one product.Sun, 09 Aug 2026 00:00:00 GMThttps://miguelrujas.com/en/notes/rolling-out-ai-in-an-sme/https://miguelrujas.com/en/notes/rolling-out-ai-in-an-sme/Three decisions, in this order. Most of the complexity in an AI rollout is in the pricing pages, not in the decision itself.Sun, 26 Jul 2026 00:00:00 GMT